COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION
CollPlant adds LightSolver’s CEO to its board as it closes the LightSolver deal and moves into photonic high‑performance computing alongside its biotech business.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) appointed Dr. Ruti Ben Shlomi, CEO and Co‑Founder of LightSolver, to its Board of Directors, effective immediately following the completion of CollPlant's acquisition of LightSolver announced on September 3, 2026.
LightSolver develops a proprietary Laser Processing Unit (LPU), an all‑optical, energy‑efficient photonic computing platform designed to accelerate computationally intensive workloads in scientific simulation, engineering, optimization and Physical AI. CollPlant states that Dr. Ben Shlomi's deep expertise in photonic computing and entrepreneurship will support the commercialization of this newly acquired technology.
With the LightSolver acquisition, CollPlant expands from regenerative medicine into advanced high‑performance computing, aiming to address demanding workloads in aerospace, defense and Physical AI while continuing its collagen-based 3D bioprinting, tissue repair and medical aesthetics activities.
Details
Market move: CLGN +4.04% in the Sep 4 session. post-acquisition board appointment
On Sep 4, the day this news came out, CLGN closed 4.04% above the previous close. Argus tracked a peak move of +29.6% during that session. Argus tracked a trough of -3.7% from its starting point during tracking. Our momentum scanner recorded 16 alerts for this stock that day. Relative volume reached 3.5x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 4 session.
Key Figures
- Appointment Date
- September 4, 2026
- Board appointment announcement
- Professional Experience
- Over 15 years
- Quantum, atomic, molecular physics and photonic computing
- LightSolver Founded
- 2020
- Co-founded by Dr. Ruti Ben Shlomi
- Bioprinting Dimension
- 3D
- Tissue and organ bioprinting
Historical Context
-
Acquisition completed; equity-centric transaction included shares, warrants and a $5 million investment.
-
One-for-ten reverse split took effect for split-adjusted trading on September 4.
-
Definitive LightSolver acquisition announced with shares, warrants and 2028 commercial availability target.
-
A $2.6 million private placement priced shares and warrants at $0.34.
-
Q1 revenue fell to $73,000 while net loss widened to $3.1 million.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
photonic computing technical
all-optical computing technical
3d bioprinting medical
recombinant human collagen medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
LightSolver Founder and CEO brings deep scientific and entrepreneurial expertise to CollPlant's Board as the Company advances the commercialization of its newly acquired photonic computing technology
REHOVOT,
LightSolver is pioneering a new generation of high performance computing based on the physics of light. Its proprietary Laser Processing Unit (LPU), an energy-efficient, pure photonic computing platform that uses coupled lasers to perform computation, is designed to accelerate computationally intensive workloads across scientific simulation, engineering, optimization and Physical AI.
"We are delighted to welcome Dr. Ruti Ben Shlomi to CollPlant's Board of Directors," said Yehiel Tal, Chairperson and Chief Executive Officer of CollPlant. "Ruti is an accomplished physicist and entrepreneur whose pioneering work in photonic computing has established LightSolver at the forefront of deep-tech innovation. Her deep scientific expertise and entrepreneurial vision will be invaluable to our Board as CollPlant advances LightSolver's commercialization and builds its position in high-performance and photonic computing."
Dr. Ruti Ben Shlomi commented, "I am honored to join CollPlant's Board of Directors as we begin this next chapter. The completion of this transaction creates an important opportunity to accelerate LightSolver's transition from technology validation to commercialization and help establish photonic computing as a new computing layer for some of the world's most demanding computational workloads. I look forward to working closely with the Board and executive team to as we advance this next phase of LightSolver's development and create long-term value for our shareholders."
Dr. Ruti Ben Shlomi is the CEO and Co-Founder of LightSolver. She is an expert physicist with over 15 years of experience spanning quantum, atomic, and molecular physics, photonic computing and technology leadership. Prior to co-founding LightSolver in 2020, Dr. Ben Shlomi conducted groundbreaking research at the Weizmann Institute of Science, where she built ultra-cold atom and cold ion systems to study complex quantum signatures. Earlier in her career, she served as a process engineer at Intel Corporation.
Dr. Ben Shlomi holds a Ph.D. in Quantum and Atomic/Molecular Physics from the Weizmann Institute of Science, an M.Sc. in Physics from Ben-Gurion University of the Negev, and a B.Sc. in Biophysics from Bar-Ilan University.
About CollPlant
CollPlant is a pioneering technology company operating at the forefront of both regenerative medicine and advanced high-performance computing. Following the strategic acquisition of LightSolver, CollPlant has expanded its footprint into the deep-tech sector, integrating a proprietary all-optical computing architecture known as the Laser Processing Unit (LPU). This bold diversification positions the Company to address some of the world's most computationally intensive workloads across aerospace, defense, and Physical AI, while continuing to drive its core biotech innovations.
In the healthcare sector, CollPlant is ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics. The Company's products are based on its recombinant human collagen produced with CollPlant's proprietary plant-based genetic engineering technology, addressing indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
For more information about CollPlant, visit www.CollPlant.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the acquisition of LightSolver by CollPlant; the anticipated benefits, strategic rationale and growth opportunities arising from the transaction; LightSolver becoming a subsidiary of CollPlant; the future development, commercialization and market adoption of LightSolver's Laser Processing Unit (LPU) technology; and the future prospects, business plans and growth strategies of CollPlant, LightSolver and the combined business. Forward-looking statements can be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "may," "should," "could," "might," "seek," "target," "will," "project," "continue" and similar expressions or the negative of such terms. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the ability of the parties to satisfy the conditions to closing the transaction and consummate the transaction on the anticipated timeline or at all; the risk that the anticipated benefits of the transaction are not realized, or are not realized within the expected timeframe; risks associated with integrating LightSolver's business, operations and personnel; LightSolver's ability to achieve anticipated technological and commercial milestones; uncertainties regarding market acceptance and adoption of LightSolver's technology; the ability to develop and commercialize LightSolver's products and technology successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition and technological developments; intellectual property risks; the availability of capital; CollPlant's ability to maintain compliance with Nasdaq listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described in CollPlant's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent Reports on Form 6-K. Forward-looking statements speak only as of the date of this press release. CollPlant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Contact Information:
CollPlant
Eran Rotem
Deputy CEO & CFO
eran@collplant.com
+972.73.232.5600
LightSolver Ltd.
Dr. Ruti Ben Shlomi
Founder & CEO
ruti@lightsolver.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-appoints-dr-ruti-ben-shlomi-to-its-board-of-directors-following-closing-of-lightsolver-acquisition-302870018.html
SOURCE CollPlant
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.